Temporal Hematologic Alterations in Women Receiving Pharmacotherapy for Breast Cancer: A Prospective Analysis
5 affiliations
- 1Internal Medicine Specialist Study Program, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
- 2Department of Internal Medicine, Dr. Soetomo General Academic Hospital, Surabaya, Indonesia.
- 3Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia.
- 4Integrated Oncology Unit, Universitas Airlangga Hospital, Surabaya, Indonesia.
- 5Division of Hematology and Medical Oncology, Department of Internal Medicine, Haji General Hospital, Surabaya, Indonesia.
Abstract
Background:: Breast cancer pharmacotherapy commonly results in hematologic toxicity and systemic inflammatory shifts that may compromise treatment tolerance. This study evaluated baseline hematologic characteristics and early hematologic changes following pharmacotherapy among patients treated in second-referral centers in Indonesia.
Methods:: This prospective cohort study enrolled 106 women with confirmed breast cancer between January and October 2025. Hematologic evaluations were performed before treatment and at Weeks 1 and 3. Assessed parameters included hemoglobin, leukocyte and platelet counts, differential counts, the neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), monocyte–lymphocyte ratio (MLR), and the pan-immune-inflammation value (PIV). Friedman’s two-way analysis of variance by ranks was used for pre–post comparisons. Subgroup comparisons between survivors and non-survivors used Mann–Whitney U tests.
Results:: The mean age was 51.9 ± 9.7 years, with most patients presenting with locally advanced disease (58.5%) and invasive ductal carcinoma (84%). Baseline hemoglobin averaged 11.9 g/dL and leukocyte count 7.5 × 10³/µL. Marked hematologic suppression occurred after therapy: leukocyte and absolute neutrophil counts declined significantly at week 1 with partial recovery by week 3 (p <0.001). Inflammatory indices showed substantial fluctuations, with significant changes in PLR, MLR, and PIV (all p <0.001). Anemia increased from 51.9% at baseline to 74.0% post-therapy. Neutropenia occurred in 1.9% at baseline, 41.7% at week 1, and 1.1% at week 3. Among survival subgroups, only MLR differed significantly (p = 0.043).
Conclusion:: The mean age was 51.9 ± 9.7 years, with most patients presenting with locally advanced disease (58.5%) and invasive ductal carcinoma (84%). Baseline hemoglobin averaged 11.9 g/dL and leukocyte count 7.5 × 10³/µL. Marked hematologic suppression occurred after therapy: leukocyte and absolute neutrophil counts declined significantly at week 1 with partial recovery by week 3 (p <0.001). Inflammatory indices showed substantial fluctuations, with significant changes in PLR, MLR, and PIV (all p <0.001). Anemia increased from 51.9% at baseline to 74.0% post-therapy. Neutropenia occurred in 1.9% at baseline, 41.7% at week 1, and 1.1% at week 3. Among survival subgroups, only MLR differed significantly (p = 0.043).
Related
- Feasibility study of the Care-at-Home Pharmacotherapy Service (CAHPS): pharmacy technician-led home visits for people receiving polypharmacy who are housebound living in socioeconomically deprived areas
- Quality of Life Among Patients with Hematologic Malignancies Receiving Outpatient Care: Associations with Socioeconomic, Clinical, Psychological, and Physical Factors
- Pre-Stroke Cardiovascular Pharmacotherapy and Early Systemic Hemodynamics After Acute Ischemic Stroke: A Prospective Multicenter Cohort Study
- Water Vapor Thermal Therapy with Rezūm Versus Combination Pharmacotherapy for Male Lower Urinary Tract Symptoms due to Benign Prostatic Obstruction: 1-Yr Results From a Prospective, Multicenter, Pragmatic Randomized Controlled Trial (VAPEUR-RCT)
- Association between microwave ablation and remission in patients with Graves’ hyperthyroidism receiving continuous antithyroid drug treatment: a single-arm prospective study
BibTeX
@article{sutanto2026temporal,
title = {{Temporal Hematologic Alterations in Women Receiving Pharmacotherapy for Breast Cancer: A Prospective Analysis}},
author = {Henry Sutanto and Merlyna Savitri and Ami Ashariati and Een Hendarsih and Pradana Zaky Romadhon and Muhammad Noor Diansyah and Putu Niken Ayu Amrita and Siprianus Ugroseno Yudho Bintoro},
journal = {Asian Pacific Journal of Cancer Prevention : APJCP},
year = {2026},
month = jun,
doi = {10.31557/apjcp.2026.27.6.2301},
url = {https://doi.org/10.31557/apjcp.2026.27.6.2301},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Temporal Hematologic Alterations in Women Receiving Pharmacotherapy for Breast Cancer: A Prospective Analysis
AU - Henry Sutanto
AU - Merlyna Savitri
AU - Ami Ashariati
AU - Een Hendarsih
AU - Pradana Zaky Romadhon
AU - Muhammad Noor Diansyah
AU - Putu Niken Ayu Amrita
AU - Siprianus Ugroseno Yudho Bintoro
PY - 2026
DA - 2026/06/22
JO - Asian Pacific Journal of Cancer Prevention : APJCP
DO - 10.31557/apjcp.2026.27.6.2301
UR - https://doi.org/10.31557/apjcp.2026.27.6.2301
AB - Background:: Breast cancer pharmacotherapy commonly results in hematologic toxicity and systemic inflammatory shifts that may compromise treatment tolerance. This study evaluated baseline hematologic characteristics and early hematologic changes following pharmacotherapy among patients treated in second-referral centers in Indonesia. Methods:: This prospective cohort study enrolled 106 women with confirmed breast cancer between January and October 2025. Hematologic evaluations were performed before treatment and at Weeks 1 and 3. Assessed parameters included hemoglobin, leukocyte and platelet counts, differential counts, the neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), monocyte–lymphocyte ratio (MLR), and the pan-immune-inflammation value (PIV). Friedman’s two-way analysis of variance by ranks was used for pre–post comparisons. Subgroup comparisons between survivors and non-survivors used Mann–Whitney U tests. Results:: The mean age was 51.9 ± 9.7 years, with most patients presenting with locally advanced disease (58.5%) and invasive ductal carcinoma (84%). Baseline hemoglobin averaged 11.9 g/dL and leukocyte count 7.5 × 10³/µL. Marked hematologic suppression occurred after therapy: leukocyte and absolute neutrophil counts declined significantly at week 1 with partial recovery by week 3 (p <0.001). Inflammatory indices showed substantial fluctuations, with significant changes in PLR, MLR, and PIV (all p <0.001). Anemia increased from 51.9% at baseline to 74.0% post-therapy. Neutropenia occurred in 1.9% at baseline, 41.7% at week 1, and 1.1% at week 3. Among survival subgroups, only MLR differed significantly (p = 0.043). Conclusion:: The mean age was 51.9 ± 9.7 years, with most patients presenting with locally advanced disease (58.5%) and invasive ductal carcinoma (84%). Baseline hemoglobin averaged 11.9 g/dL and leukocyte count 7.5 × 10³/µL. Marked hematologic suppression occurred after therapy: leukocyte and absolute neutrophil counts declined significantly at week 1 with partial recovery by week 3 (p <0.001). Inflammatory indices showed substantial fluctuations, with significant changes in PLR, MLR, and PIV (all p <0.001). Anemia increased from 51.9% at baseline to 74.0% post-therapy. Neutropenia occurred in 1.9% at baseline, 41.7% at week 1, and 1.1% at week 3. Among survival subgroups, only MLR differed significantly (p = 0.043).
SN - 1513-7368
SN - 2476-762X
ER -